These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 17457461)
1. Rimonabant as potential treatment for the neglected epidemic of diabetes in the Middle East and Arabian Peninsula. Implication for prevention. Ahmed MH Saudi Med J; 2007 May; 28(5):806-8. PubMed ID: 17457461 [No Abstract] [Full Text] [Related]
2. [Positive influence on cardiovascular risk factor by blocking the endocannabinoid system]. Chatterjee T; Ritz A; Ince H; Nienaber ChA; Rehders TC Praxis (Bern 1994); 2008 May; 97(11):613-21. PubMed ID: 18592956 [TBL] [Abstract][Full Text] [Related]
4. [In diabetes cannabinoid antagonist kills two birds with one stone]. MMW Fortschr Med; 2005 Sep; 147(35-36):10. PubMed ID: 16180564 [No Abstract] [Full Text] [Related]
5. The endocannabinoid system and cardiovascular risk: pathophysiologic role and developing therapeutic interventions. Sander GE; Giles TD Am J Geriatr Cardiol; 2006; 15(4):255-9. PubMed ID: 16849895 [No Abstract] [Full Text] [Related]
6. [Endocannabinoids receptor blocker lets tumble not only money. A drug against metabolic syndrome?]. Aumiller J MMW Fortschr Med; 2004 Nov; 146(45):12. PubMed ID: 15581096 [No Abstract] [Full Text] [Related]
7. [A new pill for metabolic syndrome. Successful control of lipids, kilos and cigarettes]. Einecke D MMW Fortschr Med; 2004 Mar; 146(13):10-1. PubMed ID: 15219119 [No Abstract] [Full Text] [Related]
8. [Rimonabant--a panacea for patients with metabolic syndrome?]. Broncel M; Koziróg M Pol Arch Med Wewn; 2006 Aug; 116(2):787-93. PubMed ID: 17424926 [No Abstract] [Full Text] [Related]
10. Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors. Tonstad S Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):156-62. PubMed ID: 16487916 [TBL] [Abstract][Full Text] [Related]
11. [Endocannabinoids--the new option in the treatment of metabolic syndrome and in smoking cessation]. Kvasnicka T Cas Lek Cesk; 2005; 144(2):81-4; discussion 85. PubMed ID: 15807291 [TBL] [Abstract][Full Text] [Related]
12. [Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies]. Scheen AJ; Van Gaal LG; Després JP; Pi-Sunyer X; Golay A; Hanotin C Rev Med Suisse; 2006 Aug; 2(76):1916-23. PubMed ID: 16972542 [TBL] [Abstract][Full Text] [Related]
13. Drug development. Drugs inspired by a drug. Marx J Science; 2006 Jan; 311(5759):322-5. PubMed ID: 16424309 [No Abstract] [Full Text] [Related]
15. [The role of the cannabinoid system in the pathogenesis and treatment of alcohol dependence]. Pietrzak B; Dunaj A; Piątkowska K Postepy Hig Med Dosw (Online); 2011 Sep; 65():606-15. PubMed ID: 21934185 [TBL] [Abstract][Full Text] [Related]
16. Inhibitors of cannabinoid receptors and glucose metabolism. Scheen AJ; Paquot N Curr Opin Clin Nutr Metab Care; 2008 Jul; 11(4):505-11. PubMed ID: 18542014 [TBL] [Abstract][Full Text] [Related]
17. [Pharmacology of cannabinoid receptors]. Le Fur G; Rinaldi-Carmona M; Barth F; Alexander J Bull Acad Natl Med; 2007; 191(4-5):933-8; discussion 938-40. PubMed ID: 18225447 [TBL] [Abstract][Full Text] [Related]